Correction  by unknown
Therapeutic options in patients with
obstructive hypertrophic cardiomyopathy and
severe drug-refractory symptoms
In their editorial comment, Fananapazir and McAreavey (1) to our
mind provide only a very selective overview of the available literature
on the therapy of patients with HOCM. For patients with HOCM who
fail to benefit from drug therapy, they consider DDD pacing or
chemical septal ablation first choice, preferably as part of a random-
ized prospective trial. “Only patients who fail to benefit from one of
these two therapies may be considered for the alternative treatment
modality or for cardiac surgery” (1).
However, Fananapazir and McAreavey themselves mention the
high complication rate of chemical septal ablation with a high need for
temporary and permanent pacemaker implantation and potential late
complications such as increased incidence of bradyarrhythmias and
tachyarrhythmias, as well as aggravation of left ventricular (LV)
dysfunction. Despite these remarks and the very small and short
experience with this technique, they surprisingly suggest chemical
septal ablation as one of the two first therapeutic choices (1).
Regrettably, their description of the literature of surgery for
HOCM is only a summation of alleged complications. “A high
mortality rate—although declining—and a high complication rate such
as 65% need for permanent pacemakers, venticular septal defect,
aortic regurgitation, progressive LV dysfunction as well as a 1% to 2%
cumulative annual mortality” are their reasons for not considering
surgery as a first choice therapeutic option (1). However, they appar-
ently overlooked our publication in Circulation in 1994 on 38 patients
who underwent Morrow septal myectomy (2). In this group there were
no perioperative deaths and only one patient died during follow-up
(mean 6.8 years) due to a myocardial infarction (2). Meanwhile, we
have extended our series to 55 patients with no additional periopera-
tive mortality. The complication rate in the whole group remains low:
only two permanent pacemakers and one well tolerated, small, ven-
tricular septal defect. During follow-up only one patient needed aortic
valve replacement for aortic regurgitation and none of the patients
experienced progressive LV dysfunction. All but one patient experi-
enced a major functional improvement (2). These results show that
surgery is an excellent therapeutic option.
In our opinion DDD pacing has to prove to be at least as good as
surgery to become the number one therapy. With respect to the results
with DDD pacing, some comments have to be made. First, the patients
with DDD pacing have a higher mean rest gradient (35 mm Hg) than
patients who underwent septal myectomy (15 mm Hg). Such a high rest
gradient of .15 mm Hg has been shown to be an independent
predictor of mortality after myectomy. Second, long-term follow-up
data of pacing are still limited (1). Third, not all patients improve with
pacing and some even become worse (1,4). Lastly, also the role of a
placebo effect is suggested in a number of patients with pacing (4).
Therefore, the proposed randomized, prospective trial should not
compare DDD pacing with chemical septal ablation but should study
the results of surgery versus new treatment modalities.
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CORRECTION
Belardinelli R, Georgiou D, Purcaro A. Low dose dobutamine
echocardiography predicts improvement in functional capac-
ity after exercise training in patients with ischemic cardiomy-
opathy. J Am Coll Cardiol 1998;31:1027–34.
On page 1032, the last sentence before the Discussion section
should have read, “The survival model (log-rank test) showed
significantly higher event-free survival in patients who under-
went the exercise training program (p , 0.001).” We regret
this printing error.
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